FSHD region gene 2 family member J, pseudogeneGenealiases: []
Q-omics provides the consensus-scored FRG2JP profile across patient tissues and cancer cell-line models. FRG2JP expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, FRG2JP is differentially expressed in 7, with the highest sampling consensus in BRCA. Additionally, FRG2JP RNA expression shows 6,555 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight COAD, BRCA, and TGCT as cancer lineages where FRG2JP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FRG2JP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FRG2JP survival associations across molecular data types. FRG2JP RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FRG2JP RNA expression–survival associations across cancer types. High FRG2JP expression shows unfavorable associations in COAD, KIRC, DLBC and LUSC, but favorable associations in PAAD and UCEC. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for FRG2JP RNA expression.
This table summarizes FRG2JP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for FRG2JP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FRG2JP shows lower tumor expression in BRCA and THCA and higher tumor expression in UCEC, LUSC, LUAD and LIHC. The BRCA box plot shows higher FRG2JP RNA expression in normal versus tumor tissue (log2 FC = −0.033, t-test p = .002).
This table shows molecular features associated with FRG2JP in patient tissues and cancer cell lines. In patient samples, FRG2JP shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
